LM11A 31 dihydrochloride

Pricing Availability   Qty
Description: Nonpeptide p75NTR ligand; neuroprotective
Chemical Name: (2S,3S)-2-Amino-3-methyl-N-[2-(4-morpholinyl)ethyl]pentanamide dihydrochloride
Purity: ≥95% (HPLC)
Citations (1)
Literature (3)

Biological Activity for LM11A 31 dihydrochloride

LM11A 31 dihydrochloride is a nonpeptide p75NTR ligand and nerve growth factor (NGF) antagonist. LM11A 31 blocks p75-mediated cell death, inhibits proNGF induced cell death (IC50 = 1-10 nM), increases proliferation and survival of hippocampal neural progenitors and inhibits Aβ-induced cell death (EC50 = 20 nM). In animal models of Alzheimer's disease LM11A 31 prevents and reverses atrophy of cholinergic neurites and reverses Alzheimer's pathology; in models of Huntington's disease LM11A 31 increases survival, reduces the formation of aggregates of mutant huntingtin and neuronal degeneration. Also promotes functional recovery in a mouse model of spinal cord injury. Orally available and brain penetrant.

Technical Data for LM11A 31 dihydrochloride

M. Wt 316.27
Formula C12H25N3O2.2HCl
Storage Desiccate at RT
Purity ≥95% (HPLC)
CAS Number 1243259-19-9
PubChem ID 91654620
Smiles O=C([C@@H](N)[C@@H](C)CC)NCCN1CCOCC1.Cl.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for LM11A 31 dihydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
water 31.63 100
DMSO 31.63 100

Preparing Stock Solutions for LM11A 31 dihydrochloride

The following data is based on the product molecular weight 316.27. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.16 mL 15.81 mL 31.62 mL
5 mM 0.63 mL 3.16 mL 6.32 mL
10 mM 0.32 mL 1.58 mL 3.16 mL
50 mM 0.06 mL 0.32 mL 0.63 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for LM11A 31 dihydrochloride

References for LM11A 31 dihydrochloride

References are publications that support the biological activity of the product.

Shi et al (2013) A small molecule P75NTR ligand protects neurogenesis after traumatic brain injury. Stem Cells [Epub ahead of print] PMID: 23940017

Massa et al (2006) Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J.Neurosci. 26 5288 PMID: 6707781

Tep et al (2013) Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury. J.Neurosci. 33 397 PMID: 23303920

Simmons et al (2014) A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One 9 e102136 PMID: 25153701

Simmons et al (2016) A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice. Hum.Mol.Genet. 25 4920 PMID: 28171570

If you know of a relevant reference for LM11A 31 dihydrochloride, please let us know.

Keywords: LM11A 31 dihydrochloride, LM11A 31 dihydrochloride supplier, LM11A31, dihydrochloride, p75NTR, ligands, selective, NGFR, nerve, growth, factor, receptors, Alzheimer's, Disease, neuroprotective, Trk, Receptors, Neuronal, Metabolism, 5046, Tocris Bioscience

1 Citation for LM11A 31 dihydrochloride

Citations are publications that use Tocris products. Selected citations for LM11A 31 dihydrochloride include:

H Uri et al (2017) p75NTR antagonists attenuate photoreceptor cell loss in murine models of retinitis pigmentosa. Cell Death Dis 8 e2922 PMID: 28703796

Do you know of a great paper that uses LM11A 31 dihydrochloride from Tocris? Please let us know.

Reviews for LM11A 31 dihydrochloride

There are currently no reviews for this product. Be the first to review LM11A 31 dihydrochloride and earn rewards!

Have you used LM11A 31 dihydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.